<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02149875</url>
  </required_header>
  <id_info>
    <org_study_id>605872</org_study_id>
    <nct_id>NCT02149875</nct_id>
  </id_info>
  <brief_title>Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke</brief_title>
  <official_title>A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 6th People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12
      hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a
      10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National
      Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the
      efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were
      also analyzed among the three groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>National Institutes of Health Stroke Scale Score</measure>
    <time_frame>At 11-day and 21-day after therapy</time_frame>
    <description>Scores range from 0 to 42, with higher scores indicating increasing severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barthel Index Score</measure>
    <time_frame>At 11-day and 21-day after therapy</time_frame>
    <description>Range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Acute Cerebral Stroke Within 12 Hours for the First Time</condition>
  <arm_group>
    <arm_group_label>Dl-3-n-butylphthalide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cerebrolysin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous infusion of 100 ml saline intravenous q.d. for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dl-3-n-butylphthalide</intervention_name>
    <description>Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.</description>
    <arm_group_label>Dl-3-n-butylphthalide</arm_group_label>
    <other_name>CSPC NBP Pharmaceutical Co., Ltd., Shijiazhuang, China</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerebrolysin</intervention_name>
    <description>Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.</description>
    <arm_group_label>Cerebrolysin</arm_group_label>
    <other_name>Ever Pharma, Unterach am Attersee, Austria</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 ml saline intravenous infusion once daily for 10 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Hebei Tiancheng Pharmaceutical Co., Ltd., Cangzhou, China</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute ischemic stroke within 12 hours for the first time before entry into the study

          -  National Institutes of Health Stroke Scale (NIHSS) score between 6 and 25

        Exclusion Criteria:

          -  with lacunar infarction

          -  with cerebral hemorrhagic infarction

          -  with epilepsy or epileptic persons

          -  with history of neurological diseases

          -  with myocardial infarction,

          -  with renal and hepatic abnormalities

          -  with metabolic diseases

          -  with contraindications to antiplatelet treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hao Chen, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai 6th People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <results_first_submitted>April 12, 2016</results_first_submitted>
  <results_first_submitted_qc>April 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 18, 2016</results_first_posted>
  <last_update_submitted>May 18, 2016</last_update_submitted>
  <last_update_submitted_qc>May 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 6th People's Hospital</investigator_affiliation>
    <investigator_full_name>Hao Chen</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>Dl-3-n-butylphthalide</keyword>
  <keyword>Cerebrolysin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrolysin</mesh_term>
    <mesh_term>3-n-butylphthalide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From January 2010 to May 2010, a randomized, doubleâ€‘blind trial was conducted, which involved patients with AIS in the Neurology Ward of Shanghai Jiao Tong University Affiliated Sixth People's Hospital (Shanghai, China).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dl-3-n-butylphthalide</title>
          <description>Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days
&quot;Dl-3-n-butylphthalide&quot;, &quot;Cerebrolysin&quot; and &quot;Placebo&quot; separately</description>
        </group>
        <group group_id="P2">
          <title>Cerebrolysin</title>
          <description>Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days
&quot;Dl-3-n-butylphthalide&quot;, &quot;Cerebrolysin&quot; and &quot;Placebo&quot; separately</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Intravenous infusion of 100 ml saline intravenous q.d. for 10 days
&quot;Dl-3-n-butylphthalide&quot;, &quot;Cerebrolysin&quot; and &quot;Placebo&quot; separately</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dl-3-n-butylphthalide</title>
          <description>Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days.</description>
        </group>
        <group group_id="B2">
          <title>Cerebrolysin</title>
          <description>Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Intravenous infusion of 100 ml saline intravenous q.d. for 10 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="6.3"/>
                    <measurement group_id="B2" value="66.5" spread="8.1"/>
                    <measurement group_id="B3" value="68.4" spread="4.2"/>
                    <measurement group_id="B4" value="67.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time until admission</title>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="3.0"/>
                    <measurement group_id="B2" value="5.0" spread="3.3"/>
                    <measurement group_id="B3" value="4.8" spread="3.7"/>
                    <measurement group_id="B4" value="5.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time until treatment</title>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="5.9"/>
                    <measurement group_id="B2" value="7.6" spread="3.6"/>
                    <measurement group_id="B3" value="5.6" spread="3.0"/>
                    <measurement group_id="B4" value="7.0" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148.6" spread="14.6"/>
                    <measurement group_id="B2" value="150.7" spread="13.7"/>
                    <measurement group_id="B3" value="152.5" spread="12.8"/>
                    <measurement group_id="B4" value="150.6" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.7" spread="10.7"/>
                    <measurement group_id="B2" value="85.1" spread="13.6"/>
                    <measurement group_id="B3" value="87.2" spread="12.5"/>
                    <measurement group_id="B4" value="87.0" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>National Institutes of Health Stroke Scale score</title>
          <description>The scores range from 0 to 42, with higher scores indicating increasing severity. A score of &lt; 4 represented low-degree impairment, between 4 and 15 represented medium-degree impairment, and a score of &gt; 15 represented severe-degree impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.4" spread="4.38"/>
                    <measurement group_id="B2" value="10.6" spread="4.74"/>
                    <measurement group_id="B3" value="10.2" spread="3.72"/>
                    <measurement group_id="B4" value="11.1" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Barthel Index score</title>
          <description>The scores range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.75" spread="6.38"/>
                    <measurement group_id="B2" value="22.25" spread="7.16"/>
                    <measurement group_id="B3" value="22.00" spread="6.96"/>
                    <measurement group_id="B4" value="21.33" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>National Institutes of Health Stroke Scale Score</title>
        <description>Scores range from 0 to 42, with higher scores indicating increasing severity</description>
        <time_frame>At 11-day and 21-day after therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dl-3-n-butylphthalide</title>
            <description>Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Cerebrolysin</title>
            <description>Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Intravenous infusion of 100 ml saline intravenous q.d. for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>National Institutes of Health Stroke Scale Score</title>
          <description>Scores range from 0 to 42, with higher scores indicating increasing severity</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.78" spread="2.48"/>
                    <measurement group_id="O2" value="7.80" spread="5.81"/>
                    <measurement group_id="O3" value="8.85" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" spread="2.34"/>
                    <measurement group_id="O2" value="5.90" spread="3.96"/>
                    <measurement group_id="O3" value="7.30" spread="4.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Barthel Index Score</title>
        <description>Range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence</description>
        <time_frame>At 11-day and 21-day after therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dl-3-n-butylphthalide</title>
            <description>Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Cerebrolysin</title>
            <description>Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Intravenous infusion of 100 ml saline intravenous q.d. for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Barthel Index Score</title>
          <description>Range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.25" spread="10.57"/>
                    <measurement group_id="O2" value="36.00" spread="10.81"/>
                    <measurement group_id="O3" value="31.00" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.00" spread="14.01"/>
                    <measurement group_id="O2" value="53.75" spread="13.10"/>
                    <measurement group_id="O3" value="43.75" spread="15.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 days</time_frame>
      <desc>Systematic methods include a physical examination (including heart rate, blood pressure and oxygen concentration), laboratory tests (including urine test, complete blood count, occult blood test, renal function, liver function, electrolyte and bloodâ€‘glucose), electrocardiogram, cranial CT or MRI and chest radiograph.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dl-3-n-butylphthalide</title>
          <description>Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days.</description>
        </group>
        <group group_id="E2">
          <title>Cerebrolysin</title>
          <description>Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Intravenous infusion of 100 ml saline intravenous q.d. for 10 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>TESS</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation disorder</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>TESS</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="6" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythrema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Foremost is the relatively small sample size, and only patients with moderate severity of stroke were enrolled, so the efficacy results of this study should be interpreted with caution.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Hao Chen</name_or_title>
      <organization>Shanghai Sixth People's Hospital</organization>
      <phone>02164369181 ext 8405</phone>
      <email>chenhao_316@aliyun.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

